Lev Radin / Shutterstock.com
8 March 2021Big PharmaAlex Baldwin
A deep dive into Regeneron v Kymab
On June 24, 2020, a seven-year-long legal battle between two biotech companies finally concluded in the UK.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
9 April 2019 Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.
Generics
26 February 2019 A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Big Pharma
24 August 2021 Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.
Editor's picks
Editor's picks
Americas
9 April 2019 Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.
Generics
26 February 2019 A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Big Pharma
24 August 2021 Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.
Americas
9 April 2019 Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.
Generics
26 February 2019 A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Big Pharma
24 August 2021 Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.